ABSTRACT
Objective To conduct prospective randomized controlled clinical observation on patients with nasopharyngeal carcinoma under chemotherapy and radiotherapy using inhaling therapy with recombinant human interleukin 11,and the preventing and curing effect of recombinant human interleukin 11 on radiation-induced pharyngitis is evaluated.Methods 161 cases of newly diagnosed patients with head and neck cancer were selected under the principle of informed consent and these 161 cases were divided into the observation group (87 cases) and the control group (74 cases) based on randomization principle.In the observation group,when the dose reached 20Gy,then recombinant human interleukin-11 inhaling therapy was applied `ll the end of radiotherapy,for the control group,conventional treatment was applied in the event of radioactive throat.RTOG criteria were used during the observation in patients with the occurrence and treatment of radioactive pharyngitis.Results When compared with the control group,the average time for radioactivity to appear was prolonged,the severity decreased and the healing time was shortened in the observation group,those data were statistically significant.Conclusions Recombinant human interleukin-11 inhaling therapy can prevent and cure inhalation of radioactive pharyngitis and this therapy is better than conventional treatment.It's worthy of further study and clinical application.
ABSTRACT
The aim of this study was to develop a new method for the determination of NO2 levels encountered in clinical settings as well as in environmental studies, using a bi−component atmospheric pressure ionization mass spectrometry(APIMS). Hydrogen (1%) diluted in pure argon was ionized by corona discharge in the first ionization component. Fifty ml of the analyte diluted in 250ml of composite air or carbon dioxide (CO2) was introduced into the second ionization component and analyzed. When composite air was used as the sample carrier gas, NO in the analyte was oxygenated and there was an increase in the NO2 content from that in the original analyte. However, when CO2 was used as the sample carrier gas, the level of NO2 in the analyte could be determined because CO2 did not change the NO2 content from that in the original analyte. A calibration curve with good linearity was obtained using the UG−410 APIMS system, with a regression equation of Y(%)=5.513*10-2 X(ppb) and a detection limit of 0.9ppb. Since APIMS detects NO2 directly within its system, the concentration of NO does not need to be measured. This system may be of great help in the accurate detection and determination of the concentration of low levels of NO2 during inhaled NO therapy